On Monday, July 9, President Obama signed the FDA bill which, in May, passed the House and Senate with ease. With this bill being made into law, PDUFA is authorized for a fifth time (PDUFA V) and generic companies, which were previously exempt, are now responsible for user fees.
Obstacles Facing Biosimilars
Still in its infancy in the U.S., the industry faces some growing pains.
Life Science Accelerated
Our experts are dedicated to expediting life science product development regulatory pathways.